J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
GlobalData on MSN22h
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccineThe FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
With the clinical hold now lifted, Novavax plans to resume trial activities and begin enrolling participants for the planned phase 3 studies, the release said. The hold had been imposed Oct. 16 ...
China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...
Novavax yesterday announced that the US Food and Drug Administration ... Asian Development Bank / Flickr cc The FDA announced ...
Barchart on MSN5h
S&P Futures Tick Lower as Key U.S. Inflation Data LoomsDecember S&P 500 E-Mini futures (ESZ24) are trending down -0.19% this morning as investors held back from making big bets ...
December S&P 500 E-Mini futures (ESZ24) are down -0.09%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.14% this morning as investors assessed the potential policy impact of Donald Trump’s ...
This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback